Podcasts about cancer control

News of President Biden's prostate cancer diagnosis raised both awareness and questions about how and when to communicate about a serious illness. How can patients access guidance and resources when it comes to understanding their emotions, while also sometimes needing to navigate those of friends and family? What is the role of supporters and caregivers? Our guests specialize in helping patients with these questions. They join us to share their expertise. In studio: Ronald Epstein, M.D., professor of family medicine, oncology, and medicine (palliative care) at the University of Rochester Medical Center Supriya Mohile, M.D., geriatric oncologist and professor in the Departments of Medicine, Hematology/Oncology; Surgery, Cancer Control; and the Cancer Center; and vice chair for academic affairs in the Department of Medicine at the University of Rochester Medical Center Abby Squicciarini, LMSW, oncology social work supervisor at Lipson Cancer Institute

President Joe Biden's cancer diagnosis has sparked a wave of concern, as well as questions about the disease. Who tends to get it? When should men get screened? What causes it? What are the myths, and what are the realities? Our guests answer questions from listeners about prostate cancer: Supriya Mohile, M.D., geriatric oncologist and professor in the Departments of Medicine, Hematology/Oncology; Surgery, Cancer Control; and the Cancer Center; and vice chair for academic affairs in the Department of Medicine at the University of Rochester Medical Center Thomas Osinski, M.D., assistant professor of urology at the University of Rochester Medical Center Matthew Truong, M.D., urologist who practices general urology and urologic oncology at the Center for Urology, which is associated with Rochester Regional Health

RaeAnn Tucker from the Henry and Stark County Health Departments joined Wake Up Tri-Counties to discuss National Public Health Week, Cancer Control Month, and HIV Prevention Programs. As National Public Health Week 2025 commences, the Henry and Stark County Health Departments celebrate three decades of dedicated service, underscoring the theme “30 Years—Public Health Week It Starts Here.” With a focus on prevention and health equity, efforts are pursued to foster healthier communities. April also marks Cancer Control Month, encouraging lifestyle changes to reduce cancer risks. Additionally, National Youth HIV/AIDS Day highlights crucial PrEP/HIV prevention programs available in Kewanee, Colona, and Toulon. This comprehensive initiative offers education, testing, and affordable treatment, contributing to the well-being of the community. For more details, contact the Henry & Stark Health Departments.

X101's Matt Brooks speaks with Courtney Maxson in this month's edition of the Cancer Prevention Segment to discuss cancer awareness in April. The post April is National Cancer Control Month appeared first on X101 Always Classic - WXHC.com.

The National Cancer Institute (NCI) is exploring how it can leverage artificial intelligence to enhance cancer screening techniques, ultimately improving patient outcomes across the nation. Dr. Katrina Goddard, director of the Division of Cancer Control and Population Sciences at NCI, explains how her division is leveraging AI, and other innovative solutions like the low-dose CT scan, to better detect lung cancer and enable better access to data.

Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership.Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

SpaceTime Series 27 Episode 153*The Mysterious Origins of Martian MineralsA new study suggests that some Martian minerals may have formed in liquid carbon dioxide rather than water. While traditional views link Mars' dry river channels to past water presence, this research indicates that under ancient Martian conditions, liquid CO2 could have been a significant factor in shaping the planet's geological features. This finding, published in Nature Geoscience, adds a new layer to the ongoing debate about Mars' liquid past and its implications for the planet's habitability.*Australia's Arnhem Space Centre ShutteredEquatorial Launch Australia has announced the closure of the Arnhem Space Centre due to unresolved lease issues with the Northern Land Council. Originally envisioned as a hub for commercial space launches, the project faced multiple delays over land agreements. Plans are now underway to relocate operations to Queensland, aiming to establish the Australian Space Centre, Geberic which promises significant economic benefits and indigenous employment opportunities.*Discovery of the Heaviest Antimatter ParticlePhysicists at CERN's Large Hadron Collider have identified what could be the heaviest antimatter particle ever detected. Using the ALICE experiment, researchers observed anti-hyperhelium 4, an exotic hypernucleus. This discovery provides new insights into the matter-antimatter asymmetry of the universe, as scientists continue to explore the mysteries of the Big Bang and the universe's evolution.00:00 Some Martian minerals may have been formed in liquid carbon dioxide rather than water06:01 Scientists find evidence for what appears to be the most massive antimatter particle ever detected13:15 Move of time projection chamber into ALICE detector starts very slowly15:22 The TPC is our main tracking detector for heavy ion collisions20:21 Living in an agricultural community with high pesticide use may increase cancer risk22:50 Former CNN reporter Tucker Carlson claims he was attacked by a demon while sleepingwww.spacetimewithstuartgary.comwww.bitesz.com

Geography determines whether or not you receive treatment for cancer, and whether you will suffer painfully or live with a good quality of life. This is a fact of the cancer divide, placing the disproportionate burden of cancer deaths and disabilities on the developing world. How do we dismantle the barriers to cancer care in low- and middle-income countries, and ensure that cancer isn't a death sentence because of where you live or how poor you are? We speak to Dato' Dr Saunthari Somasundaram, President of the National Cancer Society of Malaysia, and HE Dr Wahid Ali Said Al Kharusi, President & Chairperson, Oman Cancer Association, in conjunction with the National Cancer Congress Malaysia 2024.Image Credit: Oman Cancer Association Facebook

I didn't really know chemo brain is "real" until just recently. Dr. Todd Horowitz has done research on "chemo brain" - with the better term being "cancer-related cognitive impairments", or CRCI. CRCI is real, find out how it manifests, and what can help. (Spoiler alert: it is mental and physical exercise!) Todd Horowitz, PhD, is a prominent cognitive psychologist with a keen interest in understanding how the human mind processes visual information and the complexities of perception and attention. He has made significant contributions to our understanding of visual memory, visual search, and attentional mechanisms with over 70 peer-reviewed papers. He is currently Program Director in the Behavioral Research Program's Basic Biobehavioral and Psychological Sciences Branch, located in the Division of Cancer Control and Population Sciences at the National Cancer Institute. 

There is so much that we don't know in medicine, plus there is human error, and it would be great if AI could help. Dr. Todd Horowitz is an expert in attention and research on medical image perception. We talk about what you can see in a quick glance, how computer algorithms can fail, and how best to figure out how AI can help us. Dr. Todd Horowitz, PhD, is a prominent cognitive psychologist with a keen interest in understanding how the human mind processes visual information and the complexities of perception and attention. He has made significant contributions to our understanding of visual memory, visual search, and attentional mechanisms with over 70 peer-reviewed papers. He is currently Program Director in the Behavioral Research Program's Basic Biobehavioral and Psychological Sciences Branch, located in the Division of Cancer Control and Population Sciences at the National Cancer Institute. 

Dr. Shannon Westin and her guests, Dr. Emily S. Tonorezos and Dr. Michael Halpern, discuss their article, "Myths and Presumptions About Cancer Survivorship" recently published in the JCO. TRANSCRIPT The guests on this podcast episode have no disclosures to declare.   Shannon Westin:Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we go in depth on manuscripts published in the Journal of Clinical Oncology. I am your host, Social Media Editor of the JCO, Shannon Westin, and also a GYN Oncologist by trade. I'm thrilled to bring a topic that is very close to my heart. We're going to be talking about a Comments and Controversies article published in the JCO on November 16, 2023, entitled "Myths and Presumptions about Cancer Survivorship." I know you all will find this topic as enthralling as I have, and the authors do not have any conflicts of interest.  I'm joined by two of the authors on this important work. The first is Dr. Michael Halpern, he's the Medical Officer in the Health Assessment Research Branch of the Health Care Delivery Research Program. Welcome, Dr. Halpern. Dr. Michael Halpern: Thank you for having us on. Shannon Westin: We're also accompanied by Dr. Emily Tonorezos, the Director of the Office of Cancer Survivorship, and both of them work in the Division of Cancer Control and Population Sciences at the National Cancer Institute, National Institutes of Health. Welcome.  Dr. Emily Tonorezos: Thank you for having us. Shannon Westin: So, let's get right into it. I want to level set first. I would love for one or both of you to speak a little bit about the state of cancer survivorship currently. What's the prevalence of cancer survivors here in the US? Globally? What do we expect as time passes? Dr. Emily Tonorezos: Thank you for starting with this question. In the Office of Cancer Survivorship, we use a definition of cancer survivor that we got from the advocacy community many years ago. We use a definition that says “a person is a cancer survivor from the time of diagnosis through the balance of life.” That means in the United States, we estimate that we have a little over 18 million cancer survivors, and globally, it's a little more difficult to estimate those numbers. Not every country has a cancer registry to count the number of cases, but we think there are upwards of 53 million cancer survivors diagnosed within the last five years in the world. Shannon Westin: Wow. And so this is why it's so important, such a large number, and that's just an estimate. And we know this is only going to be growing. I personally learned so much from your manuscript, which is critically based on the understanding that our beliefs as practitioners truly impact the way we care for our cancer survivors. I admit, I definitely held or hold some of these beliefs, and I'm certainly grateful that you're providing that objective evidence to support or refute these claims.  So, with that being said, let's tackle the first one that you all approached: Shared care results in the best outcomes for cancer survivors. I think first I'd love to hear about what your definition of shared care is. What does that really mean in the context of cancer survivorship? Dr. Michael Halpern: Shared care is a deliberate process to coordinate and integrate components of survivorship care between specialty, in this case, oncology providers, and primary care providers. And part of the issues with this belief about shared care being the best have to do with the broad practice experience of survivorship care. While the ideal definition is this integrated and coordinated care, shared care can range from one extreme to being essentially oncologist-led care - where the oncologist also sends information to the primary care providers; and to the other extreme - care led by primary care providers and an oncologist is available to answer questions as needed. So part of the issue with the available literature is that there is a tremendous range in terms of the definition of shared care that's being used in studies. Shannon Westin: So, understanding those limitations, obviously, based on what you just said, what have we seen in some of the studies that have been exploring shared care and what it might mean for cancer survivors? Dr. Michael Halpern: So there have been some wonderful studies and some very well-done research in shared care. The majority of it indicates essentially no benefits, not any worse, but definitely not any better than other survivorship care models among multiple domains, quality of life, patient preference, clinical outcomes, in some cases, costs. So there isn't at this point a rationale for believing that shared care leads to better outcomes than does other types of models of care. And that's not to say that we don't think that shared care is a valuable model, that it's potentially very useful and beneficial for certain groups of cancer survivors. It's just that at this point, we don't have evidence to say who it is going to have optimal outcomes for compared to other kinds of survivorship care models.  Shannon Westin: And that makes sense. I mean, I think we're seeing this over and over again in all aspects of cancer care that one broad stroke or one broad plan isn't right for everybody, whether that's therapeutic or surgical or prevention, so it makes sense to me that that's what we're seeing here in survivorship as well. So I see this manuscript as a call to action about what are we missing, what data do we need to generate to really be able to move this care forward. So that makes total sense to me. And I guess in line with that, another belief, and I've heard this all the time from my patients, too, is this idea that primary care providers feel unable to provide survivorship care. They're not comfortable. “Oh, you have a diagnosis of cancer. You have to be seen there at the cancer center.” What does our evidence demonstrate here? Dr. Emily Tonorezos: This is another belief that was found to be a presumption. So that means that this is a belief that we think was true, but which convincing evidence does not confirm or disprove. So what the available evidence tells us is that primary care providers do have challenges in taking care of cancer survivors, particularly with regards to certain cancer-related care needs. But at the same time, we found lots of evidence that primary care providers are more than willing and able to take care of cancer survivors. They express confidence in their skills. They think that they are capable of taking care of cancer survivors. And especially for survivors of more common cancers, primary care providers, in general, express a lot of confidence in their ability to take care of those patients. What they might lack could be things along the lines of survivorship-specific knowledge. So that is a gap that we identified. But this idea that primary care feels unable to take care of survivors really was not supported by the evidence. Shannon Westin: I mean, and that makes sense, right? If we're seeing more and more cancer survivors, primary care is going to adapt to that. We adapt to the things we see commonly in our clinics, and that goes across all specialties. So that certainly makes sense. I guess you've already kind of said this, and I'll just highlight it for the listeners. You know, clear guidelines seem to be a clear, nice option to potentially improve this situation.  So let's discuss this next myth that you all identified, that oncology providers are hesitant to transition survivors to primary care. Now, I understand this one because I definitely, we get this a lot, and I'm a center medical director in GYN, and we've definitely tried to put patients that are free of disease out back in the community to be able to free up space for other patients. And we definitely get pushback because seeing patients that are in this state of being free of disease and they're living their life, it's inspiring. We remember why it is we're doing the things we do. What did the data show us about this myth? And are we creating barriers to this transition to survivorship care outside of the oncology centers? Dr. Emily Tonorezos: Exactly. So this belief is a myth. We found evidence that this belief is not true, and it seems to be one of those things that feels true, that oncologists want to take care of cancer survivors, that it contributes to the joy of medicine. But that evidence really does not suggest that that's the case. In fact, the opposite is true in the evidence. We found when we looked at the available research Oncologists want to take care of people who are diagnosed with cancer and need treatment. That is really what they think their role is. That's what they feel they're contributing. And so, even though there is a pleasure in seeing a person who has finished treatment, most oncologists say that the amount of time that they spend taking care of people who are done with treatment is appropriate - meaning they're not looking to expand their panel of post-treatment patients. They really want to take care of people who need treatment currently and then perhaps have a little bit mixed in of people who are done with treatment or who are in that survivorship phase. We found a lot of evidence, also hard evidence, that oncologists are, in fact, transitioning survivors to primary care. There is a lot of evidence that people who have been diagnosed with cancer are being seen in primary care and that that proportion increases over time. So if oncologists were really creating these insurmountable barriers to transition to primary care, we would not be seeing so many survivors in the primary care setting. But the fact is they're there, and they are being moved there by their providers. Shannon Westin: I love hard evidence. I do have a few patients that have said, "Can I just come see you every once in a while?" And I love seeing them, but I agree, we can't fill our panels with that. So that makes good sense.  So the next topic centers around finances, and this is the idea that survivorship clinics lose money. What truth did you all discover here regarding reimbursement for this type of care?  Dr. Michael Halpern: We discovered that this is a presumption. It's a belief that there isn't compelling evidence one way or the other. Part of the issue with this is probably some confusion about what constitutes survivorship care. There are certainly difficulties in obtaining reimbursement for certain survivorship services, such as sexual health and fertility counseling, and wellness and exercise services. It's understandable that there may be problems getting reimbursement or appropriate reimbursement for those. But when looking at overall survivorship care, there are actually very few studies that have done a financial analysis of the cost of providing that care versus the reimbursement. And those that have done more detailed analyses generally show that the reimbursement for survivorship care is greater than the cost. Survivorship care clinics actually do break even or make money.  Now, it's also true that providing survivorship care likely doesn't provide the same level of reimbursement as providing oncology treatments, which involves administering systemic agents and different kinds of imaging or diagnostic procedures. And so there are other streams of reimbursement possible for that. But overall, there really isn't compelling evidence to indicate that survivorship clinics lose money. There is a concern that having this widespread belief that they do may be a disincentive for hospitals or healthcare systems to start different kinds of survivorship clinics. Shannon Westin: I think this is an area where it would really behoove us to do more work so that we can encourage institutions to do this. And, I know in our center, the things that you're mentioning, it's exactly like the problems that these people are having around sexual health and fertility and exercise, wellness in general, I mean, those are the soft things that I feel like it's harder to kind of gain momentum to really develop established programs that really make an impact. And so I was so glad to see that you mentioned that in this paper, and I hope it will encourage people to really move that forward.  So finally, I was interested in this presumption around the shared electronic health records and how that might help with survivorship care coordination. Is this our solution for smooth communication and care of these people? Dr. Emily Tonorezos: This one was actually almost something that's sort of funny to think about, how naive we were about electronic health records. We found a number of examples from five or ten years ago where leaders in survivorship research and clinical care were saying, "Well, once we have electronic health records, we will not have these same problems of care coordination or communication." And that has just not been true, unfortunately. So this one was also a presumption, meaning the evidence of a benefit for electronic health records just was not out there. So we know that consolidation and transfer of diagnostic and treatment information can increase knowledge. So you can show that you can increase knowledge about diagnosis and treatment with a shared electronic health record. So the primary care provider is able to look, for example, at the pathology from the original diagnosis. But whether that actually results in anything in terms of improved care is an open question. Shannon Westin:I think that's what we've learned a lot about electronic health records in general. I remember when we were transitioning to our new system, and everyone thought, "Oh, this is going to be the end all, be all." And it has been good in a lot of ways, but it certainly hasn't been the cure for everything that ails us.  Well, I'm just so thrilled. Thank you all so much. This has been really educational and so important, given what we've already talked about, about the increasing population of cancer survivors that we're seeing in the clinic and globally. I think just to kind of tie a bow on it, I would just love to hear each of your bottom lines regarding kind of where we are right now with the care of our cancer survivors and what we need to be addressing maybe in the short term to move things forward. Dr. Emily Tonorezos: So I'll go first. I just want to say it's really important, I think, when we are around other investigators and in our meetings and talking about clinical care, that we think critically about the things that we hear people saying. This idea, especially the one that oncology providers don't want to transition their survivors to primary care, but the others as well. I think the way that we need to address this or carry this forward is to just be aware when we're in those settings and we hear people say things, to ask the question, "Is that really supported by the evidence?" And you may find that there are even more of these commonly held beliefs that really aren't supported by the evidence or that deserve a little bit of a deeper dive. Dr. Michael Halpern: I very much agree with that. And it's critical that we be willing to question some of these beliefs, be willing to discuss them, and not accept them as facts in order to be able to develop new research programs, hypotheses, to explore really what can help produce the best outcomes for survivors, because that's really what we're all about.   The other bottom-line issue, I think, one, Dr. Westing that you brought up, is that survivorship isn't a one-size-fits-all. The best survivorship care is the care that is tailored towards the survivor - the individual needs and wants. What kind of supports will be most effective in terms of enhancing their health? So, we really need to pay attention to the individual and, most importantly, what outcomes for survivorship care matter most to the survivor? What do they want to see happen? What do they want their subsequent future to look like? And how do we measure those outcomes to ensure that they get the best care on the terms that they want?  Shannon Westin: Well, great. I think that's a perfect place to end. I just want to, again, thank my guests. This went by so fast, and I learned a ton, and I hope all of you did as well. Again, we were discussing the Comments and Controversies manuscript "Myths and Presumptions about Cancer Survivorship" published in the JCO on November 16, 2023.  Thank you again to our listeners for joining JCO After Hours. And please do check out our other offerings wherever you get your podcasts. Have an awesome day.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

WHO has released new global cancer figures, showing stark inequities in preventing and treating cancer, with rising numbers of cases and cancer-related deaths expected to affect the countries least equipped to cope.In this episode of "Let's Talk Cancer", Isabelle Soerjomataram, researcher and epidemiologist at the International Agency for Research on Cancer, WHO's cancer branch, analyses and interprets these global cancer trends. Hosted on Acast. See acast.com/privacy for more information.

Professor Jasmin Tiro is a professor of Public Health Sciences at the University of Chicago She is the Associate Director of Cancer Prevention and Population Science at the NCI-Designated Comprehensive Cancer Center at the University of Chicago. Her program of research identifies multi-level determinants of cancer prevention and early detection behaviors. She uses quantitative and qualitative methods to develop, test, and implement interventions.  In 2014, Professor Tiro received the Outstanding Mentorship Award from the Center for Translational Medicine at UT Southwestern. In this episode, you will hear her share how her passion for science and experiments led her to the field of Public Health.

Debra L. Friedman, M.D., is a professor of Pediatrics in the Division of Hematology and Oncology at the Monroe Carell Jr. Children's Hospital at Vanderbilt. She is the E. Bronson Ingram Chair of Pediatric Oncology and the leader of the Cancer Control and Prevention Program and directs the Cancer Survivorship programs at the Vanderbilt-Ingram Cancer Center. Dr. Friedman's research interests lie in the long term outcomes for cancer survivors, as well as in the design of novel therapeutic protocols for childhood cancer, designed to decrease adverse long-term effects of therapy. She has leadership roles in Children's Oncology Group (COG) and is an internationally recognized expert in cancer survivorship, participating in projects evaluating best practices and models of care. She is investigating a diverse group of physiologic and psychosocial outcomes among survivors of pediatric cancer, hematopoietic stem cell transplant and medical oncology. Friedman completed her pediatric residency and a joint fellowship in Pediatric Hematology/Oncology and Cancer Epidemiology at the University of Pennsylvania and The Children's Hospital of Philadelphia (CHOP). Prior to coming to Vanderbilt in 2008, she served as the co-director of the Cancer Survivorship Program at CHOP and then, as the founder and director of the Fred Hutchinson Cancer Research Center Survivorship Program. ---- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

This episode was brought to you in partnership with HealthyWomen with support from Merck.We've partnered with HealthyWomen to debunk the myths and confusion surrounding HPV and cervical cancer. In our episode today, we dive into the basics of HPV and cervical cancer, their interwoven connection, common myths and the importance of vaccines and screening. Listen in as our guests, Dr. Pierce and Tamika Felder, share their insights as advocates in the fieldListen and Learn:What is HPV and how does it relate to cervical cancer?What are the symptoms of HPV that women and men should be aware of?Stigmas around HPV and cervical cancer that we need to eradicateHow cervical cancer impacts pregnancyTamika's path to parenthoodAbout Dr. Pierce:Dr. Jennifer Young Pierce was recruited to MCI from the Medical University of South Carolina, where she served as GYN Oncology Disease Team Leader at Hollings Cancer Center and Associate Professor in Obstetrics and Gynecology. With a degree in medicine from MUSC and degrees in engineering and public health from the University of Virginia – Charlottesville, Dr. Pierce became the first female gynecologic oncologist in South Carolina in 2009. Dr. Pierce served on the National HPV Roundtable as well as on the cervical cancer and immunotherapy committees for the NRG, the cooperative clinical trials group of the NCI. She is the Division Director of Cancer Control and Prevention at Usa health mitchell cancer institute and host of the cancering show podcast. Dr. Pierce treats patients suffering from gynecologic malignancies, including all medical and surgical aspects.About Tamika Felder:Tamika Felder is a beacon of hope and resilience for people navigating their own challenges around the world. Whether delivering a captivating talk or working as an award-winning TV producer, Tamika is all about driving change. Notably, as a cervical cancer survivor, she founded Cervivor, Inc. in 2005 to empower women to share their stories and take control of their well-being. She lends her sought-after voice to Presidential Panels, international conferences, and media outlets, and is the author of "Seriously, What Are You Waiting For? 13 Actions To Ignite Your Life & Achieve The Ultimate Comeback" as well as her own blog at tamikafelder.com. In intimate conversations, public stages, and the written word, Tamika's brilliance shines as she transforms her experiences into inspiration.You can catch the entire episode on YouTube here: https://www.youtube.com/@thegreatgirlfriends—————————Sybil would love your feedback... If you enjoyed this episode, tell her why!Leave her a review and make sure you subscribe on your favorite podcast platform.Send Sybil a DM directly to www.instagram.com/sybil_amuti or an email to welcome@thegreatgirlfriends.comFollow now

Welcome to Episode 23 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Liver cancer is currently the seventh deadliest cancer in Australia. Liver cancer mortality rates in Australia continue to grow faster than any other cancer. Incidence rates 3 times higher among men than women and the survival rate is just over 20 per cent.Our Host Rachael Babin chats to Associate Professor Eleonora Feletto about efforts to transform Liver Cancer Control in Australia.  Eleonora leads the Gastrointestinal Cancers Policy and Evaluation Stream at the Daffodil Centre. Her current work focuses on the prevention and early detection of colorectal and liver cancer in Australia and overseas.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter,  a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us

Attempts to cure cancer have spanned centuries and been influenced by culture, region and religion. Those working to understand and treat cancer have faced similar problems throughout history.Thanks to modern medicine, we are constantly seeing better survival rates. Yet cancer remains a leading cause of death worldwide. Looking at the past can provide valuable lessons in understanding cancer and managing innovation.In this episode, Cary Adams, CEO of UICC, speaks with Professor Yolanda Eraso, from London Metropolitan University, and with Carsten Timmermann, from the University of Manchester. Hosted on Acast. See acast.com/privacy for more information.

This episode I sit down with Dr. Anthony Chaffee, a neurosurgeon and longtime carnivore, for an eye-opening conversation on the benefits of a meat-based diet. He shares how nutritional research has been influenced by biased studies and religious beliefs, and discusses the weak association between red meat and cancer. He also delves into the physiological effects of carbohydrates on our metabolic system and the potential benefits of a ketogenic diet for hormone regulation and cancer management. His passion for neurosurgery and functional medicine shines through as he explores the powerful role of food as medicine and the impact of diet on our overall health. Join us as we explore the fascinating world of a carnivore diet and learn how it can unleash our true potential. Dr. Anthony Chaffee Instagram Dr. Thiago Lusvarghi Instagram 0:00 - Rapid fire questions 0:15 - Where did you grow up? 0:25 - Where do you live now? 0:42 - What's one of your favorite books? 2:44 - What's one of your super powers? 4:34 - What is holding people back from finding success in their health? 5:54 - Dr. Anthony Chaffee's Carnivore Journey 6:64 - Plants contain several carcinogenic compounds (Paper by Bruce Haynes) 13:30 - How did you find the transition from whole foods diet to pure carnivore? 15:30 - How Artificial sweeteners impact you 17:25 - Why is carbohydrate elimination beneficial? How carbs impact our bodies | PCOS in women (type 4 diabetes) 20:35 - How a ketogenic diet impact our body 22:54 - Leptin and insulin signalling 25:22 - How fructose impacts our body (ghrelin, leptin, and insulin) 27:26 - Fructose is metabolized the same as alcohol and gives dopamine signals just like meth, cocaine, and heroin. 32:29 - Why fructose should be regulated 33:24 - Why vegan breastmilk does not nourish the baby 37:29 - Is it okay to eat fruit in season or any at all? 39:35 - Oxalates above 150mg-200mg/day is damaging. 1 cup of spinach has 700mg 43:55 - fruits today have higher sugar content 44:45 - Surviving ice age conditions with meat, not plants. 45:05 - Isn't saturated fat bad for us? 51:05 - Red meat doesn't cause colon cancer, the evidence is extremely weak. 53:31 - Blue zones studies 54:00 - problems with epidemiological studies about meat 56:00 - how they decided that meat was bad 59:44 - Cancer is a Metabolic Disease (Dr. Thomas Seyfried) 1:00:40 - How cancer starts in our body and what drives it 1:03:00 - Role of mitochondria in cancer 1:09:00 - How a ketogenic diet increases chemo/radiation effectiveness 1:10:00 - Glioblastoma and Glutamine + Case Studies 1:19:00 - Are there any benefits to eating Broccoli? 1:23:00 - Maasai and Kikuyu 1930 nutritional study 1:25:00 - Plant Anti-Nutrients 1:28:00 - Sulfurophane toxicity 1:33:15 - What biomarkers should we observe to maintain health? 1:35:00 - B12 less than 400 can cause neurological damage + reference range 1:36:30 - Magnesium, Calcium, Zinc, Serum Thyroid Level (rT3), HDL, Triglycerides 1:40:54 - Why western medicine doesn't care about these 1:43:00 - Main markers of metabolic health (fasting HbA1C, insulin, glucose) 1:45:26 - Optimal range for free testosterone (600-900) 1:47:55 - Insulin blocks human growth hormone 1:50:29 - Testosterone and estrogen for females 1:53:40 - reverse T3, free T3 1:55:25 - How much does Dr. Chaffee spend on groceries? 1:58:20 - What does Dr. Anthony Chaffee eat in a day? 2:00:00 - How much meat should you eat in one sitting? 2:02:02 - Does Dr. Anthony Chaffee drink milk? 2:02:40 - Does Dr. Anthony Chaffee ever eat carbs or plants? 2:04:27 - Do you add salt on your steaks? 2:07:20 - Does Grain-fed vs Grass-fed beef matter? Do free range vs commercial eggs matter? 2:09:00 - Does Dr. Anthony Chaffee take supplements? 2:11:15 - How should people transition to a carnivore diet? 2:15:11 - What is Dr. Anthony Chaffee's vision for how he wants to practice in the future?

Supplements are all around. The general idea is that supplements are "good for us" or at least neutral.  Dr. Alison Mondul walks us through why that isn't necessarily the case and how come it's so hard to get good research on them. Dr. Mondul also discusses #MiCares , a new research project that will help us understand the world around us.https://micares.health/Join Us on #theunchosenforkApple: https://apple.co/3uwyKPoSpotify: https://spoti.fi/3FuqPG4About our Guest Host:Alison Mondul, PhD, MSPH is an Associate Professor in the Department of Epidemiology at the University of Michigan School of Public Health. She completed her PhD in Cancer Epidemiology at the Johns Hopkins Bloomberg School of Public Health, her MSPH at The Emory University Rollins School of Public Health, and her BS in Microbiology at the University of Illinois at Urbana-Champaign. She is a member of the Cancer Control and Population Sciences Program at the University of Michigan Rogel Cancer Center.Dr. Mondul studies the role of modifiable risk factors in the etiology of cancer. In particular, she has studied how lifestyle factors and factors related to diet and nutrition, such as micronutrients and lipids, may influence prostate, bladder, and kidney cancers, as well as other genitourinary conditions such as benign prostatic hyperplasia, and how genetic factors may contribute to or modify these associations. More recently, she has become involved in studying head and neck cancer, which is an exciting area of inquiry as it remains an understudied cancer. Dr. Mondul is a co-investigator on the new Michigan Cancer Research and the Environment (MI-CARES) Study, which began recruitment in 2022.Support the showFollow the Unchosen Fork: Facebook Instagram TikTok Disclaimer: The contents of this podcast, including text, graphics, images, and other materials created and/or disseminated by The Unchosen Fork are for informational purposes only. The Contents are NOT intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health providers with any questions you may have regarding a medical condition, before beginning a nutritional plan and/or taking nutritional supplements. Reliance on any information provided by this podcast, others content appearing on this podcast, or other visitors to the Site is solely at your own risk. None of the contents of this podcast are intended to be relied upon for medical treatment or diagnosis. The Unchosen Fork, their affiliates, nor any of the host family members assumes any liability or responsibility for damage or injury to person or property arising from any use of any product, service, information, or instruction contained on this Podcast.

Theresa (Reese) Clark BS, MPH is the CEO of Empress Herbal Products and Principal for the Ecwiti Group.Prior to Ms. Clark taking on an entrepreneurship roles, she was an adjunct professor at Long Island University. Reese served as a public health program manager with the Office of Minority Health and Refugee Health Program in the Pennsylvania Department of Health, Office of Health Equity (OHE). She also worked to secure quality health assessments for newly arriving Pennsylvanian refugees. Prior to Reese joining the OHE, she was the senior program analyst and lead evaluator with the Division of Cancer Control and Prevention in the Pennsylvania Department of Health.Guyanese Bush Medicine is one of the best methods for improving the health and wellness for womenSpecific Guyanese herbs and practices that are used to address health topics (hormones, menstruation, skin health, gut health, std, uti, womb health, yeast infection, etc…) for women.https://www.instagram.com/empressherbalproducts/_______________________________________DivaGirl Is A Lifestyle Community That Educates And Empowers Women With Interactive Seminars, Workshops, Events, Conferences And Volunteer Trips Abroad.We provide safe and positive environments for women to connect and support each other for future collaboration. Encouraging women to lead, have fun & feel confident!Please subscribe and leave a review!Come join the tribe: DivaGirl 411 Facebook GroupCheck us out: www.divagirltribe.comFollow us: Diva Girl Tribe IG

About 90% of nonmelanoma skin cancers are associated with ultraviolet radiation exposure. Sometimes prevention is straight forward: wear sunblock, stay shaded. But still, there are 1 million skin cancer diagnoses in the U.S. every year. Ultraviolet dosimeters are one of several technologies that are showing a lot of promise when it comes to preventing skin cancer. The tools collect personalized data about UV exposure and are linked to an app that allows people to enter information about their sun-protective behaviors like wearing sunscreen.  Psychologist Frank Perna, program director at the National Cancer Institute (NCI)'s Division of Cancer Control and Population Sciences, Behavioral Research Program, and Health Behaviors Research Branch, discusses how programs like the Surveillance, Epidemiology and End Results (SEER) Program and the Classification of Laws Associated with School Students (CLASS) are helpful in tracking melanoma as well as capturing data about state policies related to sun safety and sunscreen use in schools.

2023 will be a big year for the Surveillance, Epidemiology and End Results (SEER) Program as it celebrates 50 years of using data to monitor trends and support research on the diagnosis, treatment and prevention of cancer. The SEER Program, which is funded by the National Cancer Institute, is making significant strides to decrease the burden of cancer through a suite of analytical tools that better capture data and make it more accessible to the research community. Steve Friedman, senior advisor for operations with the Surveillance Research Program in the Division of Cancer Control and Population Sciences at NCI, unpacks two new data initiatives, the Virtual Bio-Repository and the Virtual Pool Registry, that will allow researchers to collect additional clinical data and remove barriers for conducting multi-site cancer studies.

Matt, Sarah, and Doug unpack all things science communication! We talk with Dr. Sarah Vos from UK Department of Health Management and Policy and the Director of Undergraduate Research in the College of Public Health. We discuss communication spanning many scientific disciplines, bridging the gap between science and the public, disaster communication, getting your message to stick, building trust, and why it all matters! About our guest: Sarah C. Vos, Ph.D., is an assistant professor in the Department of Health Management and Policy and the Director of Undergraduate Research in the College of Public Health at the University of Kentucky. Her research explores how public health organizations can use social media and other short message systems to improve health outcomes, particularly during a public health crisis. Her work has been published in Cancer Control, Health Security, Risk Analysis, and the Journal of Health Communication. In her free time, she likes to run, hike, and watch birds. 

During The Economist's 8th Annual World Cancer Series congress in Brussels last month, web editor Nicole Raleigh sat down to discuss the event and its themes with Greg Rossi, senior vice president, head of oncology Europe and Canada at AstraZeneca .

The discovery of the link between HPV and cervical cancer came in the 1980s and the research continues today, with researchers like our featured guest, Dr. Heather Brandt. Tune in to hear about how Dr. Brandt's research has helped transform the landscape of addressing disparities in cancer prevention and how working with allies and partners has effectively increased HPV vaccination. Dr. Heather Brandt is the director of the HPV Cancer Prevention Program at St. Jude Children's Research Hospital and co-associate director for outreach at the St. Jude Comprehensive Cancer Center. She also serves as a full member of the Department of Epidemiology and Cancer Control. She is a faculty affiliate at the University of Memphis School of Public Health and the University of South Carolina Arnold School of Public Health. Beyond the podcast, check out St. Jude's HPV Cancer Prevention Program. They have a number of campaigns, initiatives, plus online and local events. Join in the conversation by using #CervivorPodcast! For more Cervivor-related content, check out: Cervivor.org. Follow Cervivor on all social media platforms. If you would like to be interviewed as a potential guest for an upcoming episode or would like to request a speaker or topic for a future podcast episode, email us at info@cervivor.org. --- Support this podcast: https://anchor.fm/cervivor/support

Held under the theme “The Continuum Care for Better Cancer Control and Management”, the conference is organised by the Friends of Cancer Patients (FOCP) in collaboration with the Gulf Federation for Cancer Control and the Gulf Centre for Cancer Control and Prevention (GCCCP). We speak to Dr Iffat Al Barazi from UAE University and Khawla Rashid from FOCP during the event.

Samar Alhomoud (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) discusses her review on progress and remaining challenges for cancer control in the Gulf Cooperation Council.Read the full article:Progress and remaining challenges for cancer control in the Gulf Cooperation Council

Welcome to the series finale of The Cancer Mavericks. In this final episode, we reflect on the first seven episodes through the lens of history and progress with a series of insightful conversations featuring some of healthcare's most influential and visionary voices across the past four decades. If history is a teacher, we have learned that change can happen, albeit slowly. But it is only when the people stand up, organize and activate their voices demanding change, that the culture will shift, the institutions will pivot, and the very system itself will be forced by the will of the citizens to bend towards the arc of justice. Thank you for joining us for this groundbreaking series. If you like this series, please leave a review and a rating on your favorite podcast app. To learn more about The Cancer Mavericks, visit https://CancerMavericks.com. To learn more about OffScrip Health, visit https://OffScrip.com.FEATURED VOICESGil BasheChair Global Health and Purpose, FINN PartnersJohn D. Carpten, Ph.D.President's Cancer Panel (Emeritus)Director, Institute of Translational GenomicsKeck School of Medicine at USCDeanna DarlingtonPresident at Links2EquityKenny KaneYoung Adult Cancer Advocacy PioneerCo-Founder/CEO, Stupid Cancer (Former)Margaret LawsPresident and CEO, Hope LabLisa C. Richardson, MD, MPHDivision Director, Cancer Prevention and Control at The CDCCatharine Young, Ph.D.Assistant Director of Cancer Moonshot Engagement and PolicyThe White HouseSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Co-hosts Stephanie Winn and Chris Joyce sit down with Moon S. Chen, Jr., Ph.D., M.P.H. of the UC Davis Comprehensive Cancer Center. Dr. Chen is a nationally renowned expert in cancer health disparities, particularly as they affect Asian-American populations. He is the Cancer Center's Associate Director for Cancer Control, leading a research portfolio that addresses cancer risk determinants and their mitigation in human populations. He also co-leads the Population Sciences and Health Disparities research program for the Cancer Center. To find out more about the Office of Community Outreach and Engagement, visit https://ucdavis.health/ocoe. To learn more about the UC Davis Comprehensive Cancer Center, visit https://health.ucdavis.edu/cancer.

Today on That Tech Pod, Laura and Gabi speak with AI experts, PAI's Rebecca Finlay and Ernst & Young's Todd Marlin.Rebecca Finlay is the CEO at Partnership on AI overseeing the organization's mission and strategy. In this role, Rebecca ensures that the PAI Team and our global community of Partners work together so that developments in AI advance positive outcomes for people and society.Most recently, Rebecca was Vice President, Engagement and Public Policy at CIFAR. In this role, Rebecca founded the Institute's global knowledge mobilization practice, bringing together experts in industry, civil society, and government to accelerate the societal impact of CIFAR's research programs. In 2017, she was responsible for the launch of CIFAR's AI & Society program to support international working groups on the questions AI poses for all aspects of policy and society. In 2019, she launched CIFAR Solution Networks to support multi-year, international teams in the development of responsible approaches to real-world applications of AI. She led CIFAR's partnerships with governments and public sector organizations, diversifying the organization's funding sources internationally.Prior to joining CIFAR, Rebecca held leadership roles in research and civil society organizations including as Group Director, Public Affairs and Cancer Control for the Canadian Cancer Society and National Cancer Institute of Canada. She began her career in the private sector building strategic partnerships, including as First Vice President, Financial Institution and Partnership Marketing for Bank One International. In 2019, Rebecca was honored as a Fellow of the American Association for the Advancement of Science (AAAS). In 2022, she was appointed to the Strategic Advisory Council of the Information and Privacy Commissioner of Ontario. She holds degrees from the University of Cambridge and McGill University. She is an active volunteer and lives with her family in Toronto, Canada.Todd Marlin is a principal in Ernst & Young LLP's Forensic & Integrity Services practice and is the Global Forensic Technology and Innovation Leader. Mr. Marlin is a trusted advisor to the C-suite, board of directors and General Counsel on complex issues surrounding data, security and legal and compliance risks. His main focus areas are forensic data analytics,cybersecurity, computer forensics, fraud detection, and electronic discovery. Adept in big data analytics and data science, his team helps clients develop custom models to identify, expose and demonstrate relationships, trends and patterns within complex and disparate data. Mr. Marlin applies his extensive experience in data analytics and computer forensics to help businesses monitor, investigate, mitigate and recover from cyber breaches, as well asfraudulent and criminal activities by rogue employees. Mr. Marlin has led numerous global projects for Fortune 500 companies and worked with both inside and outside counsel to navigate data and security challenges in critical situations and to manage legal, regulatory and financial risks. His unique background in accounting and technology enables him toeffectively work with multi-disciplinary stakeholders in complex legal, security and compliance issues. He has appeared on behalf of clients in front of the NYSE and SEC. Mr. Marlin has also served as a Neutral Expert and an Expert and has been appointed in Federal Court as a Special Master relating to electronic discovery disputes.www.thattechpod.com

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel's take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel's take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel's take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel's take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel's take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel's take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel's take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel's take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel's take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Australia continues to be steps ahead of New Zealand when it comes to cancer treatment.The Cancer Control Agency's found 20 gaps made up of 18 individual medicines which are funded across the Tasman, but not here.Since the analysis was done, two have been funded by Pharmac.Cancer Control Agency Chief Executive Diana Sarfati told Mike Hosking the overall issue goes past just medicines.She says there needs to be enough resources to be able to administer the drugs.LISTEN ABOVESee omnystudio.com/listener for privacy information.

Sophia George, PhD, is a Cancer Control and Population Health researcher with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. Dr. George is also an Associate Professor in the Division of Gynecological Oncology within the Department of Obstetrics and Gynecology. Said another way, she is a real-life superhero. Her story began in Dominica, a Caribbean island, where her family instilled a strong sense of being service oriented at a young age. She has taken that with her across a number of different places but consistently seeking to connect people. She credits the success of her journey to focusing on the roadmap to get to your destination. You will learn:How she remains curious and asks questions because the worst thing someone can do is say no.How she has navigated the twists and turns of her journey but ultimately met her goals by focusing on the roadmap.How she expands her range of sources for inspiration to stretch her capabilities and potential.Links referenced in our discussion:National Institutes of HealthAmerican Cancer SocietyConnect with Dr. Sophia at:Twitter / IG / Hereditary Breast and Ovarian Cancer Lab

Dr. Emily Tonorezos is Director of the National Cancer Institute's (NCI) Office of Cancer Survivorship which is part of the Division of Cancer Control and Population Sciences. Dr. Tonorezos leads NCI's efforts to address challenges facing cancer survivors and their families. These efforts include preventing or mitigating adverse effects and improving the health and well-being […] The post Survivors? Choosing Words about People Who Have, or Have Had, a Serious Illness (HLOL #222) appeared first on Health Literacy Out Loud Podcast.

A cancer diagnosis sucks no matter what — but factors like income, education, racism, geography, housing, and access to health care, known as "social determinants of health," can worsen the burden. When researchers zoom out from individual experiences and survey cancer survivors, they see patterns called social determinants of health. Individual circumstances such as economic stability, physical environment, racial bias, proximity to a provider, or fluency in that provider's language can influence a survivor's health outcome before any cancer treatment begins. In this episode, we share stories of cancer mavericks who rebelled against the foreshadowing of health disparities. 23-year survivor Mary P. Lovato started a support group at her pueblo in New Mexico that expanded to reach American Indian and Alaska Native tribes across the United States. After learning she had breast cancer at 31, Maimah Karmo made it her mission to advocate for young women, Black women, and those with metastatic disease — and to end health disparities in our lifetime. Finally, health disparities researcher Dr. Carmen Guerra shares how the University of Pennsylvania's Abramson Cancer Center nearly doubled the number of Black patients in its clinical trials. For more information about this series, visit https://CancerMavericks.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For decades, the portrayal of cancer in movies and television was grim. If a character was diagnosed with cancer, it was a near certainty they'd be dead by the credits. But, like cancer treatment itself, Hollywood evolved, and many storylines about cancer became stories of survival.In this episode, we ask the question, "Who influences us and why?" From musicians to television stars, film producers to televised cancer screenings, when celebrities lend their voices to raising awareness and fundraising, that kind of star power can move mountains. Join us as we hear from voices such as actor Patrick Dempsey, StandUp2Cancer Co-Founders Katie Couric, Pam Williams, the late Laura Ziskin. Also appearing in this episode: Steven Hoffman (Professor of Global Health Law and Political Science at York University in Toronto, Canada,) Dr. Larissa Nekhlyudov (Director of Internal Medicine for Cancer Survivors at the Dana Farber Cancer Institute,) Kami Kosenko (Professor of Communication at North Carolina State University,) and Milton Kent (Former reporter and sports columnist for The Baltimore Sun).For more information about this series, visit https://CancerMavericks.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Facing a diagnosis of cancer at any age is horrible. But for young adults, it's just plain different. Not better. Not worse. Different. Those diagnosed between the ages of 15 and 39 are on a planet all their own, often left to fend for themselves as lost voices sandwiched between pediatrics and adult cancer. The consequences of living with, through, and, ideally, beyond cancer carries with it a whole host of unique long-term issues, issues that had fallen under the radar and gone ignored by the system for far too long.In this episode, we talk to a new generation of cancer mavericks like Tamika Felder, Heidi Adams, Doug Ulman, and Lindsay Nohr-Beck, who revived a dying national conversation on cancer survivorship in the earliest days of the Internet. They created edgy websites, forced doctors to listen by creating fertility preservation guidelines, and fought to bring the invisible and underserved voice of the young adult cancer community into the national public spotlight.For more information about this series, visit https://CancerMavericks.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In just over 20 years, the number of cancer survivors in the United States has doubled to 17 million survivors, each confronting their new (ab)normal lives. From chemo brain to PTSD, medical debt to workplace discrimination, this episode follows survivors along with their unique—and often difficult—paths post-treatment. In this episode, we hear from some of the godmothers of the cancer survivorship movement like Dr. Patricia Ganz and Barbara Hoffman and “everyday mavericks” who are forging ahead into life after cancer. For more information about this series, visit https://CancerMavericks.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Advocacy can take many forms in the cancer community — from advocating for yourself or a loved one to receive the best possible treatment to calling your Congressperson or testifying on Capitol Hill to demand increased access to care. This episode explores different ways cancer mavericks have elevated survivors' needs and improved their lives, including the pioneering patient navigation model created by Dr. Harold Freeman at Harlem Hospital, the story of Ellen Stovall's fearless and collaborative approach to policy, shaped around a shared agenda to represent the needs of all cancer survivors, and the landmark 1998 March on Washington called Coming Together To Conquer Cancer. For more information about this series, visit https://CancerMavericks.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

By the 1980s, cancer was no longer a death sentence. But the question of what surviving actually meant was unanswered. Cancer survivors had to navigate issues around employment, relationships, and the emotional and physical side effects of treatment in a world that largely didn't know what to do with them. (and they were still called “victims.”) In 1985, a young doctor named Fitzhugh Mullan wrote an essay called “Seasons of Survival” about his own experience with cancer. His piece helped popularize the term “cancer survivor” and resonated with a growing number of survivors, who were starting to form support groups around the country. Among them was Catherine Logan Carrillo, the founder of People Living Through Cancer in New Mexico, who asked Fitzhugh to help her convene an “alumni association” for cancer survivors. And they did, during one monumental weekend in Albuquerque. For more information about this series, visit https://CancerMavericks.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mary Lasker used to say that more money was spent on advertising campaigns for gum than was spent on cancer research. She'd seen the effects of that almost non-existent budget first hand: she watched people close to her die from cancer, including her advertising exec husband. She was outraged by the lack of money and research devoted to ending the disease. But with her own funds and influence, Mary Lasker rallied the public and lawmakers to take notice, ultimately leading to The National Cancer Act of 1971. This "War on Cancer" brought millions of dollars, but also harsh truths: there was no simple cure for cancer, and the remedies of modern science to control the disease took a devastating toll on patients. Rose Kushner was one of those patients. She questioned the treatments and surgeries that had become the status quo for medical experts. Her pushback helped start a massive change in the patient-doctor relationship as well as in cancer treatment. In Episode 1, we learn how Mary Lasker and Rose Kushner became two of the most important health policy advocates of the 20th century, putting cancer—and cancer patients—front and center. For more information about this series, visit https://CancerMavericks.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Most people don't know that you're considered a cancer survivor at the moment of diagnosis. It wasn't always this way. Sixty years ago, a cancer diagnosis was a death sentence. And if you did survive, you were left to figure out the rest of your life on your own.But some survivors demanded something different, something better.From OffScrip Media, this is The Cancer Mavericks, a deep-dive narrative into the people who fought for better treatment, forced doctors to listen, and pushed America to see the human side of the disease. Episodes of this series will publish monthly through the end of December 2021 to commemorate the 50th anniversary of the signing of the National Cancer Act of 1971. For more information, visit https://cancermavericks.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.